ArticleMicrobiology spectrum2025
Development of a double-antigen sandwich ELISA for rapid and accurate detection of antibodies against Capripoxvirus.
Article in Microbiology spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Visual typing detection of bovine leukemia virus with a lateral flow immunoassay based on latex microspheres.Archives of virology · 2026Article
- Comparison of multiple antigens for use in indirect ELISAs for detection of anti-capripoxvirus antibodies in sheep, goats, and cattle.Journal of clinical microbiology · 2026Article
- Development of an indirect enzyme-linked immunosorbent assay based on the nucleocapsid protein of bovine parainfluenza virus type 3.Frontiers in cellular and infection microbiology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lumpy skin disease, goatpox, and sheeppox have rapidly spread in many countries, leading to the emergence of new mutant strains that have caused substantial damage and posed significant threats to animal husbandry in endemic areas. Effective surveillance and disease control necessitate a simple and precise diagnostic method for detecting antibodies against Capripoxvirus (CaPV). In the present study, a double-antigen sandwich enzyme-linked immunosorbent assay (DAgS-ELISA) based on the 122 protein expressed early in viral replication and with high immunogenicity and conservation was developed to detect antibodies against lumpy skin disease virus (LSDV), goatpox virus (GTPV), and sheeppox virus (SPPV). The receiver operating characteristic (ROC) was performed to identify the best threshold value using 109 negative and 57 positive samples. The established test exhibited an area under the curve (AUC) of 0.997, and the test achieved a diagnostic sensitivity of 94.7% and a specificity of 96.3% when the S/P value threshold was set at 0.304. This method can detect the positive standard serum at a dilution of 1:32. The performances of the DAgS-ELISA were highly consistent with the commercial kit in testing 150 clinical serum samples, which were very similar (kappa value = 0.759). Moreover, the analysis of antibody dynamics revealed that the results exhibited higher sensitivity in early detection of total antibodies compared with the commercial kit. In conclusion, the DAgS-ELISA method demonstrated excellent repeatability, user-friendliness, and the ability to provide early detection of CaPV antibodies, which is highly suitable for epidemiological studies and evaluation of vaccine-induced antibody responses. IMPORTANCE: In this study, a double-antigen sandwich ELISA was developed based on the 122 protein with high immunogenicity and conservation during early viral replication, aiming to detect antibodies against Capripoxvirus. This method features high sensitivity and specificity, is cost-effective, simple, reproducible, and suitable for extensive testing. It can detect antibodies at an early phase and serves as a powerful tool for epidemic monitoring, prevention, and control.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.